First Patient Dosed in Renal Cancer Imaging Study in Japan
Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in Japan
Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product
Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT trial
Recommencement of ZIRCON Phase III Trial Recruitment in EU
Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in Europe.
Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American patients
NDA Clinical Briefing Package Submitted to the US FDA
Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product TLX591-CDx1
ZIRCON Phase 3 IND Submitted to the US FDA
Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for TLX250-CDx
TLX101 for Brain Cancer IPAX-1 Study Update
Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma multiforme
Telix Pharmaceuticals Program Update Q3 2019
Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3, 2019.
Telix Cleared to Commence Renal Cancer Imaging Study in Japan
Telix Pharmaceuticals Limited is pleased to announce the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-CDx (89Zr-girentuximab) in Japan.
First Australian Patient Dosed in ZIRCON Phase III Trial
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at Olivia Newton-John Cancer and Wellness Centre (Austin Health) on 20th August 2019, as part of the international ZIRCON (Zirconium Imaging in Renal Cancer Oncology) study.